Background: Anti-phospholipid syndrome (APS) is systemic autoimmune disorder defined as presence of anti-phospholipid antibodies with multiple obstetric complications. miR-146a-5P and miR-155-5P regulate APS and its associated inflammatory cytokines. Purpose: Our aim is to study expression levels of miR-146a-5p, miR-155-5p and pro-inflammatory cytokine interleukin-8 (IL-8) among pregnant females having APS. Research design: It is a case-control study. Data Collection and Analysis: Case group consisted of 50 pregnant women having APS. Control group consisted of 50 healthy pregnant women. Expression levels of miR-146a-5p and miR-155-5p were determined by quantitative reverse transcription polymerase chain reaction method (qPCR). IL-8 levels were determined using enzyme-linked immunosorbent assay (ELISA). Results: miR-146a-5p (mean ± SD), p value (confidence interval (CI)) among APS group versus Control group = (0.95 ± 0.7) versus (0.27 ± 0.4); 0.01 (0.44-0.90). miR-146a-5p had area under curve (AUC) of 0.813, sensitivity 66% & specificity 86%. miR-155-5p (mean ± SD); p value (CI) among APS group versus Control group = (0.57 ± 1.0) versus (0.48 ± 0.7); 0.60 (−0.25−0.43). miR-155-5p had (AUC) of 0.582, sensitivity 92% & specificity 40%. (mean ± SD); P value (CI) of IL-8 in APS group versus control group = (6.11 ± 1.2) versus (5.19 ± 0.5); CI(−0.36− 0.52), p < .001. Conclusion: miR-146a-5p significantly higher among APS group. IL-8 significantly more predominates among APS group. Alterations in miRNA expression are involved in thrombosis associated pregnancy complications.
TanYLiuQLiZ, et al.Pyroptosis-triggered pathogenesis: new insights on antiphospholipid syndrome. Front Immunol; 14: 1-12. https://doi.org/10.3389/fimmu.2023.1155222Epub ahead of print 2023.
2.
LuoXPanCGuoX, et al.Methylation mediated silencing of miR-155 suppresses the development of preeclampsia in vitro and in vivo by targeting FOXO3. Mediat Inflamm2022; 26: 1-20. https://doi.org/10.1155/2022/4250621Epub ahead of print 2022.
3.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis2006; 4: 295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
4.
ErtonZBSevimEDe JesúsGR, et al.Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository (€ registry’). Lupus Sci Med; 9: 1-10. https://doi.org/10.1136/lupus-2021-000633Epub ahead of print 2022.
NiznikSRapoportMJAvneryO, et al.Long term follow up of patients with primary obstetric antiphospholipid syndrome. Front Pharmacol; 13: 824775. https://doi.org/10.3389/fphar.2022.824775Epub ahead of print 2022.
7.
HooperABacalVBedaiwyMA. Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. Am J Reprod Immunol; 90: e13761. https://doi.org/10.1111/aji.13761Epub ahead of print 2023.
8.
RodriguesVDOSoligoADGESPannainGD. Antiphospholipid antibody syndrome and infertility. Rev Bras Ginecol Obstet2019; 41: 621–627. https://doi.org/10.1055/s-0039-1697982
KnightJSBranchDWOrtelTL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ2023; 380: e069717. https://doi.org/10.1136/bmj-2021-069717Epub ahead of print.
11.
MohamadMAAhmad AsnawiAWSuhimanMS, et al.Placenta microRNA profile of patient with obstetric antiphospholipid syndrome. Malays J Pathol2023; 45: 425–440.
12.
NagyDShaheenNHSelimHM, et al.MicroRNA-126 and 146a as potential biomarkers in systemic lupus erythematosus patients with secondary antiphospholipid syndrome. Egypt Rheumatol2020; 42: 201–206. https://doi.org/10.1016/j.ejr.2020.05.002
13.
Pérez-SánchezCAguirreMARuiz-LimónP, et al.Atherothrombosis-associated microRNAs in antiphospholipid syndrome and systemic lupus erythematosus patients. Sci Rep2016; 6: 31375. https://doi.org/10.1038/srep31375Epub ahead of print.
14.
KotylaPJIslamMA. Microrna (Mirna): a new dimension in the pathogenesis of antiphospholipid syndrome (APS). Int J Mol Sci; 21: 2076. https://doi.org/10.3390/ijms21062076Epub ahead of print 2020.
15.
GyslerSMMullaMJGuerraM, et al.Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of toll-like receptor 8. Mol Hum Reprod2016; 22: 465–474. https://doi.org/10.1093/molehr/gaw027
16.
Lopez-PedreraCBarbarrojaNPatiño-TrivesAM, et al.New biomarkers for atherothrombosis in antiphospholipid syndrome: genomics and epigenetics approaches. Front Immunol2019; 10: 764. https://doi.org/10.3389/fimmu.2019.00764
17.
Van Den HoogenLLRossatoMLopesAP, et al.MicroRNA downregulation in plasmacytoid dendritic cells in interferon-positive systemic lupus erythematosus and antiphospholipid syndrome. Rheumatology2018; 57: 1669–1674. https://doi.org/10.1093/rheumatology/key159
18.
ZhouCZhaoLWangK, et al.MicroRNA-146a inhibits NF-κB activation and pro-inflammatory cytokine production by regulating IRAK1 expression in THP-1 cells. Exp Ther Med2019; 18: 3078–3084. https://doi.org/10.3892/etm.2019.7881Epub ahead of print.
19.
ShenHHFanYWangYN, et al.Elevated circulating Interleukin-17 levels in patients with systemic lupus erythematosus: a meta-analysis. Immunol Investig2020; 49: 662–675. https://doi.org/10.1080/08820139.2019.1699107
20.
PajaresMJAlemany-cosmeEGoñiS, et al.Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside. Int J Mol Sci; 22: 7350. https://doi.org/10.3390/ijms22147350Epub ahead of print 2021.
21.
ŠtokUČučnikSSodin‐šemrlS, et al.Extracellular vesicles and antiphospholipid syndrome: state‐of‐the‐art and future challenges. Int J Mol Sci; 22: 4689. https://doi.org/10.3390/ijms22094689Epub ahead of print 2021.
22.
LvQWangYTianW, et al.Exosomal miR-146a-5p derived from human umbilical cord mesenchymal stem cells can alleviate antiphospholipid antibody-induced trophoblast injury and placental dysfunction by regulating the TRAF6/NF-κB axis. J Nanobiotechnol; 21: 419. https://doi.org/10.1186/s12951-023-02179-5Epub ahead of print 2023.
23.
DaiRAhmedSA. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res2011; 157: 163–179. https://doi.org/10.1016/j.trsl.2011.01.007
24.
HuangYHaoJLiaoY, et al.Transcriptome sequencing identified the ceRNA network associated with recurrent spontaneous abortion. BMC Med Genom; 14: 278. https://doi.org/10.1186/s12920-021-01125-4Epub ahead of print 2021.
25.
KimSParkMKimJY, et al.Circulating miRNAs associated with dysregulated vascular and trophoblast function as target-based diagnostic biomarkers for preeclampsia. Cells2020; 9: 1–17. https://doi.org/10.3390/cells9092003
26.
ShahidiMNazariFGhanbarianH, et al.miR-146b-5p and miR-520h expressions are upregulated in serum of women with recurrent spontaneous abortion. Biochem Genet2022; 60: 1716–1732. https://doi.org/10.1007/s10528-021-10173-5
27.
ShumnalievaRKachakovaDShoumnalieva-IvanovaV, et al.Whole peripheral blood miR-146a and miR-155 expression levels in systemic lupus erythematosus patients. Acta Reumatol Port2018; 2018: 217–225.
PerngDWYangDMHsiaoYH, et al.MiRNA-146a expression positively regulates tumor necrosis factor-α-induced interleukin-8 production in mesenchymal stem cells and differentiated lung epithelial-like cells. Tissue Eng2012; 18: 2259–2267. https://doi.org/10.1089/ten.TEA.2011.0634
30.
AmroucheLDesbuissonsGRabantM, et al.MicroRNA-146a in human and experimental ischemic AKI: CXCL8-dependent mechanism of action. J Am Soc Nephrol2017; 28: 479–493. https://doi.org/10.1681/ASN.2016010045
